67319-56-6|Cholylglycyltyrosine|((R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycyl-L-tyrosine|-范德生物科技公司

Cholylglycyltyrosine

NMR下载 COA and HPLC MSDS下载
names：
((R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycyl-L-tyrosine
CAS号：
67319-56-6
MDL Number：
MF(分子式)： C35H52N2O8 MW(分子量)： 628.8
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Cholylglycyltyrosine
英文别名	Cholylglycyltyrosine; Chol-gly-tyr; 125I-Cgtyr; Cholyl-glycyl-tyrosine; I-Cholylglycyltyrosine;
CAS号	67319-56-6
SMILES	C[C@@H]([C@H]1CC[C@H]2[C@@H]3[C@@H](C[C@@H]4C[C@@H](CC[C@@]4([C@H]3C[C@@H]([C@]12C)O)C)O)O)CCC(NCC(N[C@H](C(O)=O)Cc5ccc(O)cc5)=O)=O
Inchi	InChI=1S/C35H52N2O8/c1-19(4-11-30(42)36-18-31(43)37-27(33(44)45)14-20-5-7-22(38)8-6-20)24-9-10-25-32-26(17-29(41)35(24,25)3)34(2)13-12-23(39)15-21(34)16-28(32)40/h5-8,19,21,23-29,32,38-41H,4,9-18H2,1-3H3,(H,36,42)(H,37,43)(H,44,45)/t19-,21+,23-,24-,25+,26+,27+,28-,29+,32+,34+,35-/m1/s1
InchiKey	HERYPGYAYHTUGY-KFNBCNGZSA-N
分子式 Formula	C35H52N2O8
分子量 Molecular Weight	628.8
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Cholylglycyltyrosine(CAS:67319-56-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Cholylglycyltyrosine is a new agent for hepatobiliary imaging.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Clements D, Mills C, Iqbal S, Chandler S, Elias E. Iodinated cholylglycyltyrosine: a new agent for hepatobiliary imaging. Eur J Nucl Med. 1986;11(10):401-4. PubMed PMID: 3699064.

[2]Mills CO, Freeman JF, Salt PJ, Elias E. Effect of anaesthetic agents on bile flow and biliary excretion of 131I-cholylglycyltyrosine in the rat. Br J Anaesth. 1989 Mar;62(3):311-5. PubMed PMID: 2784686.

[3] Suchy FJ, Balistreri WF, Hung J, Miller P, Garfield SA. Intracellular bile acid transport in rat liver as visualized by electron microscope autoradiography using a bile acid analogue. Am J Physiol. 1983 Nov;245(5 Pt 1):G681-9. PubMed PMID: 6638192.

[4] Miller P, Weiss S, Cornell M, Dockery J. Specific 125I-radioimmunoassay for cholyglycine, a bile acid, in serum. Clin Chem. 1981 Oct;27(10):1698-703. PubMed PMID: 7285320.

[5] Suchy FJ, Balistreri WF, Breslin JS, Dumaswala R, Setchell KD, Garfield SA. Absence of an acinar gradient for bile acid uptake in developing rat liver. Pediatr Res. 1987 Apr;21(4):417-21. PubMed PMID: 3574993.

6: Mills CO, Iqbal S, Elias E. Ileal absorption of tyrosine-conjugated bile acids in Wistar rats. Biochim Biophys Acta. 1987 Nov 6;926(2):154-9. PubMed PMID: 3663709.7: Al-Jabri AA, Wigg MD, Elias E, Lambkin R, Mills CO, Oxford JS. In vitro anti-HIV-1 virucidal activity of tyrosine-conjugated tri- and dihydroxy bile salt derivatives. J Antimicrob Chemother. 2000 May;45(5):617-21. PubMed PMID: 10797083.8: Deutsch JC, Iwahashi MM, Sutherland EM, Mapoles J, Simon FR. Characterization of the transport of a synthetic bile salt, iodinated cholyl-glycyl-tyrosine, in isolated cultured rat hepatocytes. Hepatology. 1992 May;15(5):917-22. PubMed PMID: 1314773.9: Mills CO, Iqbal S, Elias E. Synthesis and biliary excretion of tyrosine-conjugated bile salts in Wistar rats. Biochim Biophys Acta. 1986 May 21;876(3):667-76. PubMed PMID: 3707990.10: Mills CO, Martin GH, Elias E. The effect of tyrosine conjugation on the critical micellar concentration of free and glycine-conjugated bile salts. Biochim Biophys Acta. 1986 May 21;876(3):677-83. PubMed PMID: 3707991.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开